GlassScriptPhysician profile
Stephanie A Brazus
NPI 1407833882
$3,423.89
in general payments reported to CMS, 2019-2025
31 companies · $695 in 2025
The $695 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $106 · 2021: $722 · 2022: $498 · 2023: $446 · 2024: $571 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771.07 | 2019-2025 | Orilissa, Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $378.55 | 2023-2025 | Veozah |
| Pfizer INC. | $259.36 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $258.24 | 2021-2025 | |
| Exeltis, USA INC. | $246.02 | 2021-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $199.47 | 2019-2025 | |
| Hologic Sales and Service, LLC | $120.42 | 2019-2025 | Novasure, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima |
| Millicent US INC | $114.35 | 2024-2025 | Femlyv, Intrarosa |
| Therapeuticsmd, INC. | $113.92 | 2021-2022 | |
| Avion Pharmaceuticals | $99.41 | 2021-2023 | Balcoltra |
| Organon LLC | $96.75 | 2021-2025 | Nexplanon |
| Shield Therapeutics INC | $88.79 | 2023-2024 | Accrufer |
| Agile Therapeutics, INC. | $87.85 | 2021-2022 | |
| Coopersurgical, INC. | $78.43 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Sumitomo Pharma America, INC. | $59.86 | 2023-2025 | Myfembree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $53.33 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $51.92 | 2023-2025 | Cologuard Collection Kit |
| Duchesnay USA Incorporated | $48.74 | 2019 | |
| Boston Scientific Corporation | $37.55 | 2019 | |
| Hologic INC | $35.97 | 2021 | |
| Minerva Surgical, INC | $33.03 | 2024-2025 | |
| Covidien LP | $31.75 | 2019 | |
| Ethicon US, LLC | $30.83 | 2019-2024 | Ethicon, Vistaseal |
| Becton, Dickinson and Company | $22.13 | 2024 | Bd Onclarity |
| Smith+Nephew, INC. | $20.14 | 2023 | Renasys Touch, Pico 7 |
| Meditrina | $17.24 | 2024 | |
| Mylan Pharmaceuticals INC. | $15.52 | 2021 | |
| Evofem Biosciences, INC. | $15.43 | 2021 | |
| Tactile Systems Technology INC | $14.05 | 2019 | |
| Ascend Therapeutics US, LLC | $13.22 | 2021 | |
| Daiichi Sankyo INC. | $10.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Brazus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.